- Home
- JUNS vs THRD Comparison
JUNS vs THRD Comparison
Compare JUNS & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- THRD
- Stock Information
- Founded
- JUNS 2015
- THRD 2019
- Country
- JUNS United States
- THRD United States
- Employees
- JUNS N/A
- THRD N/A
- Industry
- JUNS
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- JUNS
- THRD Health Care
- Exchange
- JUNS NYSE
- THRD Nasdaq
- Market Cap
- JUNS 281.4M
- THRD 335.2M
- IPO Year
- JUNS 2024
- THRD 2022
- Fundamental
- Price
- JUNS $4.40
- THRD $5.79
- Analyst Decision
- JUNS
- THRD Strong Buy
- Analyst Count
- JUNS 0
- THRD 3
- Target Price
- JUNS N/A
- THRD $20.33
- AVG Volume (30 Days)
- JUNS 490.6K
- THRD 255.8K
- Earning Date
- JUNS 02-11-2025
- THRD 11-07-2024
- Dividend Yield
- JUNS N/A
- THRD N/A
- EPS Growth
- JUNS N/A
- THRD N/A
- EPS
- JUNS N/A
- THRD N/A
- Revenue
- JUNS N/A
- THRD N/A
- Revenue This Year
- JUNS N/A
- THRD N/A
- Revenue Next Year
- JUNS N/A
- THRD N/A
- P/E Ratio
- JUNS N/A
- THRD N/A
- Revenue Growth
- JUNS N/A
- THRD N/A
- 52 Week Low
- JUNS $3.86
- THRD $5.60
- 52 Week High
- JUNS $19.51
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- THRD 21.25
- Support Level
- JUNS N/A
- THRD $5.86
- Resistance Level
- JUNS N/A
- THRD $11.78
- Average True Range (ATR)
- JUNS 0.00
- THRD 0.91
- MACD
- JUNS 0.00
- THRD -0.49
- Stochastic Oscillator
- JUNS 0.00
- THRD 3.11
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to most central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.